SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Geron (GERN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: louis mason who wrote (23)2/25/1997 1:10:00 PM
From: Boyce Burge   of 50
 
I dont know about the Amgen work, but check todays NY Times for articles on telomerase. The story has gotten much more complicated, with evidence that telomeres are really in a dynamic state getting shorter and longer on a regular cycle, rather than continually getting shorter.... and are involved in additional events as fundamental as nuclear division. There are more players too, in terms of additional genes controling the length of telos... for Geron, the story is less focused, and probably the competition is increased too, since their patents dont cover all the new phenomenon.

Still I think GERN is about correctly valued here at 12 or so.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News